Triggiani Vincenzo, Guastamacchia Edoardo, Lolli Ivan, Troccoli Giuseppe, Resta Francesco, Sabbà Carlo, Ruggieri Nadia, Tafaro Emilio
Endocrinology and Metabolic Diseases, Department of Application of Innovative Technology in Surgery, University of Bari, Bari, Italy.
Immunopharmacol Immunotoxicol. 2006;28(2):377-85. doi: 10.1080/08923970600809587.
There are few cases described in the world literature reporting an association of thymoma (with myasthenia gravis or not) with hyperparathyroidism. In these cases the hyperparathyroidism was due to the presence of an adenoma or hyperplasic parathyroid tissue either in the cervical region or in an ectopic intrathymic location.(12345) In other cases the syndrome of hypercalcemia was due to the secretion of parathyroid-related protein (PTHRP) (6) or parathyroid hormone (PTH) (7) by the thymoma itself. We report the first case, at the best of our knowledge, of a wide invasive malignant thymoma (type B3), associated with myasthenia gravis and hyperparathyroidism caused by parathyroid adenoma.
世界文献中鲜有报道胸腺瘤(无论是否伴有重症肌无力)与甲状旁腺功能亢进相关联的病例。在这些病例中,甲状旁腺功能亢进是由于颈部区域或胸腺内异位部位存在腺瘤或甲状旁腺组织增生所致。(12345)在其他病例中,高钙血症综合征是由于胸腺瘤自身分泌甲状旁腺相关蛋白(PTHRP)(6)或甲状旁腺激素(PTH)(7)引起的。据我们所知,我们报告了首例广泛侵袭性恶性胸腺瘤(B3型),伴有重症肌无力以及由甲状旁腺腺瘤引起的甲状旁腺功能亢进。